Walking Fish Therapeutics, a leader in B cell therapeutics, announced the completion of an oversubscribed Series A financing, raising a total of $73 million. The additional investment, co-led by Northpond Ventures and First Spark Ventures, included support from Terra Magnum Capital Partners.

Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells' capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.